NEW YORK (GenomeWeb News) – Gen-Probe this week said that it has begun a clinical study of its Progensa PCA3 assay, a molecular test for determining the need for a repeat prostate biopsy. The firm said that the trial would be conducted to support an application to the US Food and Drug Administration for clearance of the assay.

Gen-Probe said that it expects to enroll around 500 men, all of whom have had a negative prostate biopsy, at 10 or more clinical trial sites. It expects the trial to conclude in less than a year, after which it will file the application with FDA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.